首页 | 本学科首页   官方微博 | 高级检索  
     


Tobramycin clearance during continuous arteriovenous hemofiltration
Affiliation:1. Oh Medicine and Methodology Research Institute, Seoryeong-ro, Seosan, Chungcheongnam-do, Republic of Korea;2. Yonsei Da-on Family Medicine Clinic, Seosan, Chungcheongnam-do, Republic of Korea;3. Chung-Ang Herb Dental Clinic, Seosan, Chungcheongnam-do, Republic of Korea;4. Unimedi Plastic Surgery Clinic, Gangnam-gu, Seoul, Republic of Korea;1. Department of Critical Care Medicine, Sun Yat-Sen University First Affiliated Hospital, Guangzhou, People''s Republic of China;2. Clinical Trials Unit, Sun Yat-Sen University First Affiliated Hospital, Guangzhou, People''s Republic of China;1. Faculté de Pharmacie, Université de Montréal, Montréal, Canada;2. Service de Médecine Intensive–Réanimation, APHM, Hôpital Nord, Marseille, France;3. CEReSS–Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France;4. Aix-Marseille Université, IRD, APHM, MEPHI, Marseille, France;5. IHU Méditerranée Infection, Marseille, France;6. Aix-Marseille Univ., APHM, INSERM, CIC CPCET Service de Pharmacologie Clinique et Pharmacovigilance, INS Inst Neurosci Syst, Marseille, France
Abstract:Tobramycin concentrations during continuous arteriovenous hemofiltration (CAVH) were measured in the blood and ultrafiltrate of an anuric critically ill patient. Tobramycin pharmacokinetics demonstrated first order decline. Drug clearance was 0.9 of the ultrafiltration rate. Strategies for calculating dosing intervals of tobramycin in patients on CAVH are described.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号